Iovance Biotherapeutics (IOVA) KOL event summary

Introduction and agenda

• The event featured a five-year data analysis presentation, an introduction by the Chief Commercial Officer, and a KOL panel discussion with leading oncologists from University of Chicago, Georgetown University, and Endeavor Health, followed by an audience Q&A with executive leadership and panelists present.

• Focus was on the clinical and operational experience with a one-time cell therapy for metastatic melanoma, including real-world implementation and future growth.

KOL background and credentials

• Panel included leading oncologists Dr. Peter Prieto, Dr. Dan Olson, Dr. Geoffrey Gibney, and Dr. Bruce Brockstein from major academic and community centers, all with extensive experience in melanoma and cell therapy.

Market insights and analysis

• Over 1,000 patients have been treated with the therapy, 300+ since commercial launch, and more than 80 authorized treatment centers established in the US as of May 2025.

• 250M+ patient lives are covered, with most having private insurance, and typical financial clearance takes about three weeks.

• The global advanced melanoma patient treatment opportunity is estimated at over 70,000.

• Strong payer coverage and pending ex-US approvals in the UK, EU, and Canada.